TP508 (Chrysalin ® ) Reverses Endothelial Dysfunction and Increases Perfusion and Myocardial Function in Hearts With Chronic Ischemia

Abstract

Endothelial dysfunction (ED) is characterized by impaired nitric oxide (NO) signaling, decreased NO-dependent vasodilatation, increased vascular inflammation, and diminished response to angiogenic factors. TP508 (Chrysalin^®), an angiogenic tissue repair peptide, was tested for potential effects on myocardial revascularization and ED using a porcine model of chronic myocardial ischemia. TP508 increased perfusion in ischemic regions up to16-fold (P < .02) and doubled myocardial wall thickening (P < .02) relative to placebo controls. Ischemic arterioles exhibited impaired NO-mediated vasodilation and diminished NO production. TP508 reversed ischemic effects, increasing NO-mediated vasodilation (P < .05), endothelial nitric oxide synthase (eNOS) expression, and NO production. In human endothelial cells, TP508 stimulated eNOS activation (1.84 ± 0.2-fold; P < .02), increased NO production (85 ± 18%; P < .02), and prevented hypoxia-induced eNOS downregulation (P < .01). Thus, TP508 reverses ED both in porcine ischemic hearts and cultured human endothelial cells. These results suggest potential therapeutic benefit of TP508 in myocardial revascularization and treatment of ED-related diseases.

Keywords

thrombin peptide TP508 myocardial revascularization endothelial dysfunction nitric oxide human coronary artery endothelial cells

References

Boulanger CM Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol. 1999 ;31: 39-49.

Katz SD , Hryniewicz K. , Hriljac I. , et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005 ;111:310-314.

Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002;66:529-533.

Getz GS , Reardon CA Arginine/arginase NO NO NO. Arterioscler Thromb Vasc Biol . 2006;26:237-239.

Lloyd-Jones DM , Bloch KD The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365-375.

Suzuki M. , Takamisawa I. , Yoshimasa Y. , Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract. 2007;76:12-17.

Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis . Circ Res. 2001;88:756-762.

Rikitake Y. , Kim HH , Huang Z. , et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005;36:2251-2257.

Xu W. , Kaneko FT , Zheng S. , et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18:1746-1748.

10.

Vallet B. Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care. 2003 ;7:130-138.

11.

Musicki B. , Burnett AL Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res. 2007;19:129-138.

12.

Voisine P. , Bianchi C. , Khan TA , et al. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J Thorac Cardiovasc Surg. 2005 ;129:1414-1420.

13.

Voisine P. , Li J. , Bianchi C. , et al. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation . 2005;112(9 suppl): 1202-1207.

14.

Cebe-Suarez S. , Zehnder-Fjallman A. , Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006;63:601-615.

15.

Boodhwani M. , Sodha NR , Lahom RJ , Sellke FW The future of therapeutic myocardial angiogenesis . Shock. 2006;26:332-341.

16.

Glenn KC , Frost GH , Bergmann JS , Carney DH Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Pept Res. 1988;1:65-73.

17.

Carney DH , Mann R. , Redin WR , et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides . J Clin Invest. 1992;89:1469-1477.

18.

Stiernberg J. , Norfleet AM , Redin WR , Warner WS , Fritz RR , Carney DH Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508. Wound Repair Regen. 2000;8:204-215.

19.

Norfleet AM , Huang Y. , Sower LE , Redin WR , Fritz RR , Carney DH Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia. Wound Repair Regen. 2000 ;8:517-529.

20.

Wang H. , Li X. , Tomin E. , et al. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis . J Orthop Res. 2005;23:671-679.

21.

Sheller MR , Crowther RS , Kinney JH , et al. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res. 2004;22:1094-1099.

22.

Hedberg EL , Kroese-Deutman HC , Shih CK , et al. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res A. 2005;72:343-353.

23.

Li G. , Ryaby JT , Carney DH , Wang H. Bone formation is enhanced by thrombin-related peptide TP508 during distraction osteogenesis. J Orthop Res. 2005;23:196-202.

24.

Norfleet AM , Bergmann JS , Carney DH Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells . Gen Pharmacol. 2000;35:249-254.

25.

Ryaby JT , Sheller MR , Levine BP , Bramlet DG , Ladd AL , Carney DH Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. J Bone Joint Surg Am. 2006;88(suppl 3):132-139.

26.

Vartanian KB , Chen HY , Kennedy J. , et al. The non-proteolytically active thrombin peptide TP508 stimulates angiogenic sprouting. J Cell Physiol . 2006;206:175-180.

27.

Li G. , Cui Y. , McIlmurray L. , Allen WE , Wang H. rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. J Orthop Res. 2005;23: 680-685.

28.

Tsopanoglou NE , Papaconstantinou ME , Flordellis CS , Maragoudakis ME On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb Haemost. 2004;92:846-857.

29.

Veves A. , Akbari CM , Primavera J. , et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration . Diabetes. 1998;47:457-463.

30.

Boykin JV, Jr. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. Adv Skin Wound Care. 2000;13(4, pt 1):169-174.

31.

Arana V. , Paz Y. , Gonzalez A. , Mendez V. , Mendez JD Healing of diabetic foot ulcers in L-arginine-treated patients. Biomed Pharmacother. 2004;58:588-597.

32.

Sanada M. , Taguchi A. , Higashi Y. , et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis. 2004;176:387-392.

33.

Whitney C. , Warburton DE , Frohlich J. , Chan SY , McKay H. , Khan K. Are cardiovascular disease and osteoporosis directly linked? Sports Med. 2004;34:779-807.

34.

Serin-Kilicoglu S. , Erdemli E. New addition to the statin's effect . J Trauma. 2007;63:187-191.

35.

Giannoudis P. , Tzioupis C. , Almalki T. , Buckley R. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective . Injury . 2007;38(suppl 1):S90-S99.

36.

Li M. , Healy DR , Li Y. , et al. Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone. 2005;37:46-54.

37.

Fife C. , Mader JT , Stone J. , et al. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair Regen. 2007;15:23-34.

38.

Ladd AL , Shin AYS , Bramlet DG , Wolfe SW , Ryaby JT Phase 3 acceleration of distal radius fracture healing with a thrombin receptor binding peptide. http://www.orthologic.com/research-studies/DistalRadiusFractureHealing.pdf . Published February 16, 2007. Accessed June 8, 2008.

39.

Hedberg EL , Tang A. , Crowther RS , Carney DH , Mikos AG Controlled release of an osteogenic peptide from injectable biodegradable polymeric composites. J Control Release. 2002 ;84:137-150.

40.

Harada K. , Friedman M. , Lopez JJ , et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996;270(5, pt 2):H1791-H1802.

41.

Sellke FW , Li J. , Stamler A. , Lopez JJ , Thomas KA , Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 1996;120:182-188.

42.

Rentrop KP , Cohen M. , Blanke H. , Phillips RA Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-592.

43.

Reinhardt CP , Dalhberg S. , Tries MA , Marcel R. , Leppo JA Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol. 2001;280:H108-H116.

44.

Yamamoto K. , Ito H. , Shintani Y. , Masuyama T. Pressure-derived collateral flow index as a parameter f microvascular dysfunction in acute myocardial infarction. J Am Coll Cardiol. 2001;38:1383-1389.

45.

Hein TW , Zhang C. , Wang W. , Chang CI , Thengchaisri N. , Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003;17:2328-2330.

46.

Zhang C. , Hein TW , Wang W. , Chang CI , Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001;15:1264-1266.

47.

Sitges M. , Leivas A. , Heras M. , et al. Short-term transdermal estradiol enhances nitric oxide synthase III and estrogen receptor mRNA expression in arteries of women with coronary artery disease. Int J Cardiol. 2005;105:74-79.

48.

Zhang C. , Hein TW , Wang W. , et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension . 2004;44:935-943.

49.

McQuillan LP , Leung GK , Marsden PA , Kostyk SK , Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms . Am J Physiol. 1994;267(5, pt 2):H1921-H1927.

50.

Phelan MW , Faller DV Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol. 1996;167:469-476.

51.

Takemoto M. , Sun J. , Hiroki J. , Shimokawa H. , Liao JK Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002; 106:57-62.

52.

Brem H. , Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117: 1219-1222.

53.

Gallagher KA , Liu ZJ , Xiao M. , et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007;117:1249-1259.